- Posts: 2199
- Thank you received: 639
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
Safety:www.bloodjournal.org/content/bloodjournal/early/2015/10/16/blood-2015-07-659656.full.pdf
High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial
Discussion:"Both treatments were well tolerated in general. Most of the adverse effects were mild to moderate (graded 1 or 2) and usually resolved spontaneously after medication was completed."
...
"Of the two patients who discontinued treatment due to adverse effects in the PDN arm, one was a 74-year old woman who suffered from pneumonia and required intravenous antibiotics to control the infection; the other was a 59-year old woman with grade 3 hyperglycemia and no history of diabetes mellitus or impaired glucose tolerance.
Neither patient showed an elevation in platelet count by the time of exit. No patients exited the study due to adverse effects in the HD-DXM arm."
"Most adverse effects were tolerable. Occurrence of adverse events was more frequent and long-lasting in the PDN arm, with two cases discontinuing therapy due to adverse effects. The better tolerance of high-dose dexamethasone might be attributed to its limited duration, as adverse events in this arm were usually transient and spontaneously resolved after the completion of medication. The treatments were also well tolerated in patients ≥ 60 years. High-dose dexamethasone allowed avoidance of the safety risks associated with the long-lasting administration of prednisone."
"In conclusion, results from this prospective, multicenter, randomized, controlled study
suggest that one or two courses of high-dose dexamethasone provides a more effective and more rapid response as initial treatment of ITP, with at least comparable long-term prognosis and better tolerance when compared with conventional prednisone. High-dose dexamethasone also enables patients to avoid the burden of long-term corticosteroids."
Rob16 wrote: I think the researchers would define tolerate to mean being able to complete a course of treatment without having to discontinue treatment due to adverse effects. I don't remember reading here (on PDSA) of anyone discontinuing a course of HDD treatment for any reason. Though many have chosen not to repeat this treatment, many others have opted to use repeated courses of HDD. Admittedly, many of those who "tolerated" the drug would say that they found it "intolerable". It's a matter of semantics.
According to that article, dapsone sensitivity syndrome, when it occurs, has a 9.9% fatality rate.www.nejm.org/doi/full/10.1056/NEJMoa1213096#t=abstract
About 0.5 to 3.6% of persons treated with dapsone have a drug hypersensitivity syndrome, which was first described by Lowe and Smith in 1949 and termed “dapsone hypersensitivity syndrome” in 1951. The syndrome is a severe idiosyncratic drug reaction characterized by the clinical triad of fever, rash, and systemic involvement (most commonly of the liver and the hematologic system), which can cause severe organ dysfunction. The dapsone hypersensitivity syndrome is usually manifested 4 to 6 weeks after the initiation of therapy.
ascopubs.org/doi/full/10.1200/jco.2012.43.7509 Journal of Clinical Oncology
Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness
... and in a North American teaching hospital only 36.6% of patients treated with rituximab ... had HBV testing although rates increased to 67.4% after introduction of guidelines.
www.iwmf.com/sites/default/files/docs/Rituximab-Associated_Infections-Seminars_in_Hematology.pdf
Rituximab-Associated Infections
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.